[{"id":"5634cce6-a08c-4073-971b-86089c97d96d","acronym":"CATALINA-2","url":"https://clinicaltrials.gov/study/NCT06690775","created_at":"2025-02-25T14:11:51.367Z","updated_at":"2025-02-25T14:11:51.367Z","phase":"Phase 2","brief_title":"CATALINA-2: a Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.","source_id_and_acronym":"NCT06690775 - CATALINA-2","lead_sponsor":"TORL Biotherapeutics, LLC","biomarkers":" CLDN6 • PROC","pipe":"","alterations":" ","tags":["CLDN6 • PROC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ixotatug vedotin (TORL-1-23) • Neulasta (pegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 11/20/2024","start_date":" 11/20/2024","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-17"}]